ADAPT -Heart Valve
Evidence of Long-Term Durability: 25 patients were followed for up to 10 years; No graft failure, thromboembolic events, infections or device-related reinterventions; Echocardiographic assessment demonstrated the absence of calcification in all implants.
Most popular related searches
OVER 20,000 PROCEDURES
- ADAPT® treated tissue has already been implanted in over 20 000 procedures globally
- Learn more about how we are advancing our tissue science in structural heart with the commencement of our first in-human trial of DurAVR
LARGEST PATIENT SERIES IN CONGENITAL HEART SURGERY2
- Multi-center study (3 centers, 501 implants, 377 patients)
- Wide range of application show excellent durability for CHD repair
- No evidence of calcification (echocardiographic or radiologic)
- ADAPT® bioscaffold performs comparably in the systematic and pulmonary circulations in neonates, infants and older children
